These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28903520)

  • 41. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.
    Torres B; Rallón NI; Loncá M; Díaz A; Alós L; Martínez E; Cruceta A; Arnaiz JA; Leal L; Lucero C; León A; Sánchez M; Negredo E; Clotet B; Gatell JM; Benito JM; Garcia F
    AIDS Res Hum Retroviruses; 2014 May; 30(5):425-33. PubMed ID: 24380397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
    Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
    Mallolas J; Pich J; Peñaranda M; Domingo P; Knobel H; Pedrol E; Gutiérrez F; Barrufet P; Peraire J; Asenjo MA; Vidal F; Gatell JM
    AIDS; 2008 Jan; 22(3):377-84. PubMed ID: 18195564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
    Vesterbacka J; Nowak P; Barqasho B; Abdurahman S; Nyström J; Nilsson S; Funaoka H; Kanda T; Andersson LM; Gisslèn M; Sönnerborg A
    PLoS One; 2013; 8(1):e55038. PubMed ID: 23383047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
    Higa N; Pelz A; Birch D; Beck IA; Sils T; Samson P; Bwakura-Dangarembizi M; Bolton-Moore C; Capparelli E; Chadwick E; Frenkel LM
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):261-264. PubMed ID: 31194860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kryst J; Kawalec P; Pilc A
    PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
    Adetokunboh OO; Schoonees A; Balogun TA; Wiysonge CS
    BMC Infect Dis; 2015 Oct; 15():469. PubMed ID: 26502899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
    Shey M; Kongnyuy EJ; Shang J; Wiysonge CS
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005481. PubMed ID: 19588374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia.
    Jordan MR; Hamunime N; Bikinesi L; Sawadogo S; Agolory S; Shiningavamwe AN; Negussie T; Fisher-Walker CL; Raizes EG; Mutenda N; Hunter CJ; Dean N; Steegen K; Kana V; Carmona S; Yang C; Tang AM; Parkin N; Hong SY
    Medicine (Baltimore); 2020 Sep; 99(37):e21661. PubMed ID: 32925712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
    Ahmed BS; Phelps BR; Reuben EB; Ferris RE
    Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
    Ramos JT; De José MI; Dueñas J; Fortuny C; González-Montero R; Mellado MJ; Mur A; Navarro M; Otero C; Pocheville I; Muñoz-Fernández MA; Cabrero E;
    Pediatr Infect Dis J; 2005 Oct; 24(10):867-73. PubMed ID: 16220083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.